101 related articles for article (PubMed ID: 2475346)
1. Temperature distribution and pH changes during hyperthermic regional isolation perfusion.
van der Zee J; Broekmeyer-Reurink MP; van den Berg AP; van Geel BN; Jansen RF; Kroon BB; van Wijk J; Hagenbeek A
Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1157-63. PubMed ID: 2475346
[TBL] [Abstract][Full Text] [Related]
2. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study.
van de Merwe SA; van den Berg AP; Kroon BB; van den Berge AW; Klaase JM; van der Zee J
Int J Hyperthermia; 1993; 9(2):205-17. PubMed ID: 8468505
[TBL] [Abstract][Full Text] [Related]
3. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
Jakob J; von Rege I; Weiss C; Hohenberger P
Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
[TBL] [Abstract][Full Text] [Related]
4. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion.
Hill S; Fawcett WJ; Sheldon J; Soni N; Williams T; Thomas JM
Br J Surg; 1993 Aug; 80(8):995-7. PubMed ID: 8402100
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas.
Lejeune FJ; Lienard D; Ewalenko P
World J Surg; 1988 Jun; 12(3):345-8. PubMed ID: 3400246
[No Abstract] [Full Text] [Related]
6. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities.
Di Filippo F; Calabrò AM; Cavallari A; Carlini S; Buttini GL; Moscarelli F; Cavaliere F; Piarulli L; Cavaliere R
World J Surg; 1988 Jun; 12(3):332-9. PubMed ID: 3400244
[No Abstract] [Full Text] [Related]
7. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
[TBL] [Abstract][Full Text] [Related]
8. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
Hill S; Thomas JM
Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
10. Hyperlactacidaemia in isolated hyperthermic perfusion of tumour bearing rat limbs: a study of feasibility using a novel infusion solution.
Walgenbach S; Bermes A; Bermes U; Bittinger F; Junginger TH; Mueller-Klieser W
Int J Hyperthermia; 1999; 15(2):109-22. PubMed ID: 10323619
[TBL] [Abstract][Full Text] [Related]
11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
12. Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta.
Tominaga R; Nakano T; Shibata S; Siraishi K; Nagae S; Nakayama J; Yasui H
Artif Organs; 2001 Jan; 25(1):36-41. PubMed ID: 11167557
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912
[TBL] [Abstract][Full Text] [Related]
14. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
Hohenberger P; Bida B; Schlag PM
Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
[No Abstract] [Full Text] [Related]
15. Optimization of isolated hyperthermic limb perfusion.
Omlor G; Gross G; Ecker KW; Burger I; Feifel G
World J Surg; 1992; 16(6):1117-9. PubMed ID: 1455882
[TBL] [Abstract][Full Text] [Related]
16. Thermal induction and temperature control in the hyperthermic antiblastic regional perfusion with extra corporeal circulation.
Pace M; Filomena A; Galli A
Adv Exp Med Biol; 1990; 267():399-403. PubMed ID: 2088059
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure following hyperthermic isolation perfusion of the left leg.
Rauschecker HF; Osterloh B
Anticancer Res; 1987; 7(3 Pt B):451-3. PubMed ID: 3631905
[TBL] [Abstract][Full Text] [Related]
18. 3D numerical reconstruction of the hyperthermia induced temperature distribution in human sarcomas using DE-MRI measured tissue perfusion: validation against non-invasive MR temperature measurements.
Craciunescu OI; Das SK; McCauley RL; MacFall JR; Samulski TV
Int J Hyperthermia; 2001; 17(3):221-39. PubMed ID: 11347728
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the temperature distribution during hyperthermia treatment by isolated extremity perfusion.
Gantenberg J; Mumme A; Zumtobel V; Werner J
Int J Hyperthermia; 2001; 17(3):189-206. PubMed ID: 11347726
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.
Nagel JD; Krüger I; Ghussen F; Bode U
Cancer Chemother Pharmacol; 1991; 29(2):155-8. PubMed ID: 1760859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
